Thomas Gajewski to Animals
This is a "connection" page, showing publications Thomas Gajewski has written about Animals.
Connection Strength
2.207
-
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
Score: 0.057
-
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
Score: 0.055
-
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 05 28; 43(5):114141.
Score: 0.054
-
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2021 01; 160(2):600-613.
Score: 0.042
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.040
-
STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
Score: 0.038
-
Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019 04 17; 7(1):108.
Score: 0.038
-
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108.
Score: 0.035
-
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
Score: 0.034
-
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
Score: 0.033
-
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 02; 214(2):381-400.
Score: 0.032
-
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31.
Score: 0.032
-
The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 07 01; 126(7):2404-11.
Score: 0.031
-
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. J Immunol. 2016 08 01; 197(3):953-61.
Score: 0.031
-
Germ Warfare. Sci Am. 2016 Apr; 314(4):50.
Score: 0.031
-
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA. J Immunol. 2016 Apr 01; 196(7):3191-8.
Score: 0.030
-
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93.
Score: 0.030
-
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9.
Score: 0.030
-
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9.
Score: 0.029
-
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71.
Score: 0.029
-
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5.
Score: 0.029
-
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19; 11(7):1018-30.
Score: 0.029
-
Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74.
Score: 0.028
-
New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8.
Score: 0.028
-
Primary murine CD4+ T cells fail to acquire the ability to produce effector cytokines when active Ras is present during Th1/Th2 differentiation. PLoS One. 2014; 9(11):e112831.
Score: 0.028
-
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
Score: 0.027
-
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22.
Score: 0.026
-
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013 Aug 28; 5(200):200ra116.
Score: 0.026
-
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013 Aug 15; 191(4):1677-85.
Score: 0.025
-
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol. 2013 Oct; 55(3-4):283-91.
Score: 0.025
-
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov 19; 209(12):2157-63.
Score: 0.024
-
Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013 Feb; 34(2):67-73.
Score: 0.024
-
Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother. 2012 Aug; 61(8):1343-7.
Score: 0.024
-
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012 Mar 15; 188(6):2630-42.
Score: 0.023
-
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16.
Score: 0.022
-
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One. 2011; 6(9):e24931.
Score: 0.022
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92.
Score: 0.021
-
Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-?1 phosphorylation. J Immunol. 2011 Jan 15; 186(2):784-90.
Score: 0.021
-
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Score: 0.021
-
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 Jul-Aug; 16(4):399-403.
Score: 0.021
-
Beta-catenin does not regulate memory T cell phenotype. Nat Med. 2010 May; 16(5):513-4; author reply 514-5.
Score: 0.020
-
Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol. 2009 May 15; 182(10):6022-30.
Score: 0.019
-
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44.
Score: 0.019
-
Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol. 2009 Jan; 7(1):1-10; quiz 11-2.
Score: 0.019
-
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol. 2008 Sep; 38(9):2438-50.
Score: 0.018
-
Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res. 2008 Aug; 18(4):289-94.
Score: 0.018
-
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15; 14(10):3156-67.
Score: 0.018
-
Molecular regulation of T-cell anergy. EMBO Rep. 2008 Jan; 9(1):50-5.
Score: 0.017
-
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb 29; 331(1-2):94-102.
Score: 0.017
-
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol. 2007 Jun; 247(2):95-102.
Score: 0.017
-
The expanding universe of regulatory T cell subsets in cancer. Immunity. 2007 Aug; 27(2):185-7.
Score: 0.017
-
On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol. 2007 Apr 10; 25(11):1305-7.
Score: 0.016
-
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol. 2006 Nov; 7(11):1166-73.
Score: 0.016
-
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45.
Score: 0.016
-
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006 Oct 01; 177(7):4521-9.
Score: 0.016
-
Immune suppression in the tumor microenvironment. J Immunother. 2006 May-Jun; 29(3):233-40.
Score: 0.015
-
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2326s-2330s.
Score: 0.015
-
Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells. J Immunol. 2005 Nov 01; 175(9):5581-5.
Score: 0.015
-
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005 Apr 15; 174(8):4670-7.
Score: 0.014
-
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol. 2005 Mar 15; 174(6):3416-20.
Score: 0.014
-
Peripheral survival of naïve CD8+ T cells. Apoptosis. 2005 Jan; 10(1):5-11.
Score: 0.014
-
Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res. 2005; 31(2):107-18.
Score: 0.014
-
Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol. 2025 Jan; 46(1):61-73.
Score: 0.014
-
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Curr Opin Investig Drugs. 2004 Dec; 5(12):1279-83.
Score: 0.014
-
Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9351-6.
Score: 0.013
-
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
Score: 0.013
-
Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol Cell Biol. 2004 Feb; 24(4):1628-39.
Score: 0.013
-
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 Feb 01; 64(3):1140-5.
Score: 0.013
-
Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004; 24(4):229-37.
Score: 0.013
-
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):691-6.
Score: 0.013
-
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003 Nov 01; 171(9):4574-81.
Score: 0.013
-
T cell development and function in CrkL-deficient mice. Eur J Immunol. 2003 Oct; 33(10):2687-95.
Score: 0.013
-
Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL. Eur J Immunol. 2003 Oct; 33(10):2917-26.
Score: 0.013
-
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem. 2003 May 09; 278(19):17044-52.
Score: 0.012
-
Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents. Blood Adv. 2022 12 27; 6(24):6249-6262.
Score: 0.012
-
Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol Response Modif. 2002; 20:343-9.
Score: 0.011
-
CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8.
Score: 0.011
-
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol. 2001 May; 13(5):625-32.
Score: 0.011
-
The p815 mastocytoma tumor model. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.4.
Score: 0.011
-
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001 Mar 15; 166(6):3900-7.
Score: 0.011
-
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000 Dec 01; 165(11):6024-8.
Score: 0.011
-
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719.
Score: 0.010
-
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13.
Score: 0.010
-
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019 07 15; 25(14):4202-4210.
Score: 0.009
-
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer. 1999 Jan 18; 80(2):324-33.
Score: 0.009
-
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999; 10(3):247-60.
Score: 0.009
-
Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998 Oct 01; 161(7):3347-56.
Score: 0.009
-
Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance. Cell Rep. 2018 08 21; 24(8):2112-2126.
Score: 0.009
-
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411.
Score: 0.009
-
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 Jul 06; 188(1):205-10.
Score: 0.009
-
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol. 1997 Sep; 9(9):1259-69.
Score: 0.008
-
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.
Score: 0.008
-
Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016 09 01; 126(9):3389-402.
Score: 0.008
-
The composition of the microbiota modulates allograft rejection. J Clin Invest. 2016 07 01; 126(7):2736-44.
Score: 0.008
-
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol. 1996 Apr 15; 156(8):2909-17.
Score: 0.008
-
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
Score: 0.008
-
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol. 1996 Feb 01; 156(3):1095-100.
Score: 0.008
-
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15; 156(2):465-72.
Score: 0.008
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.007
-
Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol. 1995 Aug; 2(4):211-25.
Score: 0.007
-
Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur J Immunol. 1995 Jul; 25(7):1836-42.
Score: 0.007
-
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458.
Score: 0.007
-
Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol. 1995 Jun 01; 154(11):5637-48.
Score: 0.007
-
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52.
Score: 0.007
-
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20; 41(5):830-42.
Score: 0.007
-
"Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med. 1994 Feb 01; 179(2):481-91.
Score: 0.007
-
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses. Cancer Cell. 2014 Jan 13; 25(1):37-48.
Score: 0.007
-
Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci U S A. 1994 Jan 04; 91(1):38-42.
Score: 0.007
-
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137.
Score: 0.006
-
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013 May; 123(5):1999-2010.
Score: 0.006
-
Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol. 1993; 11:29-48.
Score: 0.006
-
Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones. Eur J Immunol. 1992 Sep; 22(9):2359-65.
Score: 0.006
-
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
Score: 0.006
-
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108.
Score: 0.006
-
Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol. 1991 Mar 15; 146(6):1750-8.
Score: 0.005
-
Differential activation of murine TH1 and TH2 clones. Res Immunol. 1991 Jan; 142(1):19-23.
Score: 0.005
-
Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones. J Immunol. 1990 Jun 01; 144(11):4110-20.
Score: 0.005
-
Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J Immunol. 1990 Jan 15; 144(2):548-56.
Score: 0.005
-
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22211-6.
Score: 0.005
-
Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol. 2009 Nov; 39(11):2981-90.
Score: 0.005
-
Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones. J Exp Med. 1989 Sep 01; 170(3):985-90.
Score: 0.005
-
Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol. 1989 Jul 01; 143(1):15-22.
Score: 0.005
-
CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells. J Immunol. 2009 Jun 01; 182(11):6736-43.
Score: 0.005
-
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52.
Score: 0.005
-
Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor. J Immunol. 1988 Oct 15; 141(8):2635-42.
Score: 0.005
-
Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988 Jun 15; 140(12):4245-52.
Score: 0.004
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.004
-
Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol. 2006 May; Chapter 3:3.13.1-3.13.15.
Score: 0.004
-
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol. 2006 May; 174(1-2):74-81.
Score: 0.004
-
An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30.
Score: 0.004
-
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14.
Score: 0.003
-
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003 Jun 16; 197(12):1721-30.
Score: 0.003
-
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47.
Score: 0.003
-
Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7.
Score: 0.003
-
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60.
Score: 0.003
-
Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
Score: 0.003
-
Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc Natl Acad Sci U S A. 2000 Dec 05; 97(25):13784-9.
Score: 0.003
-
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 01; 164(9):4433-42.
Score: 0.003
-
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer. 1999 May 05; 81(3):428-37.
Score: 0.002
-
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75.
Score: 0.002
-
Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998 Aug; 9(2):229-37.
Score: 0.002
-
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol. 1997 Nov 15; 159(10):4665-75.
Score: 0.002
-
The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 1997 Jan 27; 70(3):349-56.
Score: 0.002
-
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer. 1996 Jul 17; 67(2):303-10.
Score: 0.002
-
Blocked Ras activation in anergic CD4+ T cells. Science. 1996 Mar 01; 271(5253):1276-8.
Score: 0.002
-
From defined human tumor antigens to effective immunization? Immunol Today. 1995 Jul; 16(7):334-6.
Score: 0.002
-
Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1. J Immunol. 1995 May 01; 154(9):4363-70.
Score: 0.002
-
Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J Immunol. 1993 Jul 01; 151(1):38-47.
Score: 0.002
-
Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol. 1992 Aug 15; 149(4):1124-30.
Score: 0.001
-
Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor beta 1 and dexamethasone. Int Immunol. 1991 Nov; 3(11):1091-8.
Score: 0.001
-
CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset. J Exp Med. 1990 Jun 01; 171(6):2171-6.
Score: 0.001
-
Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells. J Immunol. 1989 Jun 01; 142(11):3754-62.
Score: 0.001
-
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors. Princess Takamatsu Symp. 1988; 19:15-27.
Score: 0.001
-
Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways. J Immunol. 1987 Dec 15; 139(12):3942-8.
Score: 0.001
-
Evidence implicating I region-restricted antigen presentation in alloantigen and nominal antigen recognition by a dual-reactive helper T lymphocyte clone. J Immunol. 1984 Sep; 133(3):1101-10.
Score: 0.001